Trial · NCT07880405
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain severity assessed by Visual Analog Scale (VAS) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | VAS scores extracted from medical records. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scores indicating greater pain severity. |
| Secondary | Pain severity assessed by Short-Form McGill Pain Questionnaire (SF-MPQ) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The SF-MPQ is a validated self-report measure of pain quality and intensity. It includes a 15-item Pain Rating Index (PRI; 11 sensory and 4 affective descriptors, each scored 0-3; total PRI range 0-45), a Present Pain Intensity (PPI) index (0-5), and a VAS (0-10). Higher PRI, PPI, and VAS scores indicate greater pain severity. Sensory scores reflect pain quality, while affective scores reflect pain-related emotional distress. Scores were extracted from medical records. |
| Secondary | Pain catastrophizing assessed by Pain Catastrophizing Scale (PCS) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The PCS is a 13-item self-report scale measuring catastrophic thoughts and feelings about pain. Each item is scored 0-4, giving a total score range of 0-52. It includes three subscales: rumination, magnification, and helplessness. Higher total scores indicate greater pain catastrophizing; a total score ≥30 is commonly used to indicate clinically relevant catastrophizing. Scores were extracted from medical records. |
| Secondary | Fractional anisotropy (FA) of corticothalamic pathways | Baseline (preoperative). | FA values measured from DTI. Higher FA indicates greater white matter integrity. |
| Secondary | Thalamic gray matter volume | Baseline (preoperative). | Gray matter volume of the thalamus measured from high-resolution T1-weighted MRI. |
| Secondary | Resting-state functional connectivity within the default mode network (DMN) | Baseline (preoperative). | Resting-state functional connectivity within the DMN was calculated from rs-fMRI data as the correlation of spontaneous BOLD signal fluctuations among key DMN regions (e.g., medial prefrontal cortex, posterior cingulate cortex/precuneus, and lateral parietal cortex). Values are typically Fisher z-transformed correlation coefficients; higher values indicate stronger within-network functional connectivity. Data were extracted retrospectively from imaging archives. |
| Secondary | Resting-state functional connectivity within the salience network (SN) | Baseline (preoperative). | Resting-state functional connectivity within the SN was calculated from rs-fMRI data as the correlation of spontaneous BOLD signal fluctuations among key SN regions (e.g., anterior insula and dorsal anterior cingulate cortex). Values are typically Fisher z-transformed correlation coefficients; higher values indicate stronger within-network functional connectivity. Data were extracted retrospectively from imaging archives. |
| Secondary | Resting-state functional connectivity within the sensorimotor network (SMN) | Baseline (preoperative). | Resting-state functional connectivity within the SMN was calculated from rs-fMRI data as the correlation of spontaneous BOLD signal fluctuations among key SMN regions (e.g., primary sensorimotor cortex, supplementary motor area, and premotor cortex). Values are typically Fisher z-transformed correlation coefficients; higher values indicate stronger within-network functional connectivity. Data were extracted retrospectively from imaging archives. |
| Secondary | Glutamate/GABA ratio in the thalamus | Baseline (preoperative). | Glutamate/GABA ratio measured by MRS in the thalamus.Glutamate is the main excitatory neurotransmitter and GABA the main inhibitory neurotransmitter; the ratio reflects the balance between excitation and inhibition in this region. Higher values indicate relatively increased excitatory or decreased inhibitory tone. The ratio is unitless. Data were extracted retrospectively from imaging archives. |
| Secondary | Glutamate/GABA ratio in the anterior cingulate cortex (ACC) | Baseline (preoperative). | Glutamate/GABA ratio measured by MRS in the ACC.Glutamate is the main excitatory neurotransmitter and GABA the main inhibitory neurotransmitter; the ratio reflects the balance between excitation and inhibition in this region. Higher values indicate relatively increased excitatory or decreased inhibitory tone. The ratio is unitless. Data were extracted retrospectively from imaging archives. |
| Secondary | Glutamate/GABA ratio in the insula | Baseline (preoperative). | Glutamate/GABA ratio measured by MRS in the insula.Glutamate is the main excitatory neurotransmitter and GABA the main inhibitory neurotransmitter; the ratio reflects the balance between excitation and inhibition in this region. Higher values indicate relatively increased excitatory or decreased inhibitory tone. The ratio is unitless. Data were extracted retrospectively from imaging archives. |
| Secondary | C-reactive protein (CRP) level | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | Serum CRP concentration measured from routine blood tests. CRP is an acute-phase reactant and a marker of systemic inflammation; higher levels indicate greater inflammatory activity. Values are typically reported in mg/L, and reference ranges may vary by laboratory. Data were extracted retrospectively from medical records. |
| Secondary | Erythrocyte sedimentation rate (ESR) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | ESR was measured from routine blood tests. It is a nonspecific marker of systemic inflammation; higher values indicate greater inflammatory activity. ESR is typically reported in mm/h, with reference ranges varying by laboratory and slightly higher in women. Data were extracted retrospectively from medical records. |
| Secondary | Quality of life assessed by SF-36 | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The SF-36 is a 36-item, validated self-report questionnaire measuring health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. It generates two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life. Scores were extracted from medical records. |
| Secondary | Sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The PSQI is a validated 19-item self-report questionnaire assessing sleep quality over the past month. It yields seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction), each scored 0-3, and a global score ranging from 0 to 21. Higher global scores indicate worse sleep quality; a global score \>5 is commonly used to indicate poor sleep quality. Scores were extracted from medical records. |
| Secondary | Depression assessed by Hamilton Depression Rating Scale (HAMD) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The HAMD is a clinician-administered scale assessing the severity of depressive symptoms over the past week. The 17-item version yields a total score of 0-52, with higher scores indicating more severe depression. Commonly used severity ranges are: 0-7 normal, 8-16 mild, 17-23 moderate, and ≥24 severe. Scores were extracted from medical records. |
| Secondary | Anxiety assessed by Hamilton Anxiety Rating Scale (HAMA) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The HAMA is a clinician-administered scale assessing the severity of anxiety symptoms. The 14-item version yields a total score of 0-56, with higher scores indicating more severe anxiety. Commonly used severity ranges are: 0-6 no anxiety, 7-13 mild, 14-20 moderate, 21-28 severe, and ≥29 very severe. Scores were extracted from medical records. |
| Secondary | Cognitive function assessed by Montreal Cognitive Assessment (MoCA) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The MoCA is a validated 30-point clinician-administered screening tool for cognitive impairment. It assesses attention, executive function, memory, language, visuospatial ability, abstraction, and orientation. Total scores range from 0 to 30, with higher scores indicating better cognitive function. A score \<26 is commonly used to indicate possible cognitive impairment (1 point is added for individuals with ≤12 years of education). Scores were extracted from medical records. |
| Secondary | Cognitive function assessed by Mini-Mental State Examination (MMSE) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The MMSE is a validated 30-point clinician-administered screening tool for cognitive impairment. It assesses orientation, registration, attention and calculation, recall, language, and visuospatial ability. Total scores range from 0 to 30, with higher scores indicating better cognitive function. A score ≤23 (or \<24, depending on education level) is commonly used to indicate possible cognitive impairment. Scores were extracted from medical records. |
| Secondary | Global efficiency of the anatomical structural network based on T1-weighted MRI | Baseline (preoperative). | T1-weighted MRI data are used to construct an individual anatomical structural network. Global efficiency is calculated as a summary metric of network integration. Higher global efficiency indicates stronger structural network integration. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07880405/registered